MFG
VERV

Merit Financial Group’s Verve Therapeutics VERV Stock Holding History

Merit Financial Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,612
Closed -$366K – 1867
2025
Q2 		$366K Buy
32,612
+5,406
+20% +$30.8K ﹤0.01% 1239
2025
Q1 		$124K Buy
27,206
+15,146
+126% +$101K ﹤0.01% 1346
2024
Q4 		$68K Buy
12,060
+535
+5% +$3.02K ﹤0.01% 1140
2024
Q3 		$55.8K Sell
11,525
-307
-3% -$1.78K ﹤0.01% 816
2024
Q2 		$57.7K Sell
11,832
-215
-2% -$1.35K ﹤0.01% 903
2024
Q1 		$77.2K Buy
12,047
+22
+0.2% +$292 ﹤0.01% 845
2023
Q4 		$168K Buy
12,025
+609
+5% +$7.55K 0.01% 741
2023
Q3 		$151K Buy
+11,416
New +$184K 0.01% 705

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Merit Financial Group's VERV Position: Q3 2025 in Review

Merit Financial Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 32,612 shares — an estimated $366K sold.

Merit Financial Group first reported a position in VERV in Q3 2023 and held it in 8 quarters. The position peaked at $366K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Merit Financial Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Merit Financial Group sold 32,612 Verve Therapeutics shares in Q3 2025, an estimated $366K.
  • Merit Financial Group first reported a position in Verve Therapeutics in Q3 2023 and held it in 8 quarters.
  • Merit Financial Group's Verve Therapeutics position peaked at $366K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Merit Financial Group's 13F filing for Q3 2025, filed 20 Oct 2025.